Filtros de búsqueda

Lista de obras de

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

artículo científico publicado en 2003

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer

artículo científico publicado en 2014

Adjuvant ovarian suppression in premenopausal breast cancer

artículo científico publicado en 2014

Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance).

artículo científico publicado en 2015

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

artículo científico publicado en 2008

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

artículo científico publicado en 2014

Different degrees of NADPH oxidase 2 regulation and in vivo platelet activation: lesson from chronic granulomatous disease

artículo científico publicado en 2014

Does NADPH Oxidase Deficiency Cause Artery Dilatation in Humans?

scholarly article by Lorenzo Loffredo published in April 2013

Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial

article

Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17

article

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

artículo científico publicado en 2006

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

article

Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study

artículo científico publicado en 2009

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

artículo científico publicado en 2003

In Reply:

Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen

artículo científico publicado en 2008

PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).

artículo científico publicado en 2016

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

article

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

artículo científico publicado en 2005

Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

artículo científico publicado en 2012

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

artículo científico publicado en 2018

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

artículo científico publicado en 2014

p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).

artículo científico publicado en 2011

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda